New Form 8-K - Cogent Biosciences, Inc. Filed: 2025-06-11 AccNo: 0001193125-25-138813 Size: 165 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements …
Notable Data on Evofems SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
Johnson & Johnson - New data show TREMFYA®(guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
SenesTech Announces Bradley Caldwell, Inc. as New U.S. Distributor for Evolve Rodent Fertility Control Products
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
McKesson Corporation - McKesson to Host Investor Day on September 23, 2025
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
NanoVibronix Inc Notification (NAOV)